
Journey Medical Corporation: updates and filings
Price
$3.69
November 18, 2026Market cap $90M
What Ploutos Investor adds for Journey Medical
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
April 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Oct 9, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 26, 2026Shareholder voteForm8-K
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 21, 2026Other material eventsForm8-K
- Apr 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 25, 2026Results of operationsForm8-K
- Jan 21, 2026FilingFormEFFECT
- Jan 15, 2026Correspondence with the SECFormCORRESP
- Jan 15, 2026Shelf registration for future offeringsFormS-3
- Dec 30, 2025Letter from the SECFormUPLOAD
- Dec 30, 2025FilingFormDRS
- Nov 12, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 12, 2025Results of operationsForm8-K
- Sep 26, 2025Material agreement entered, new material financial obligationForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Oct 9, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 26, 2026 | 8-K | Shareholder vote | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 21, 2026 | 8-K | Other material events | Document |
| Apr 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 25, 2026 | 8-K | Results of operations | Document |
| Jan 21, 2026 | EFFECT | Filing | Document |
| Jan 15, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jan 15, 2026 | S-3 | Shelf registration for future offerings | Document |
| Dec 30, 2025 | UPLOAD | Letter from the SEC | Document |
| Dec 30, 2025 | DRS | Filing | Document |
| Nov 12, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 12, 2025 | 8-K | Results of operations | Document |
| Sep 26, 2025 | 8-K | Material agreement entered, new material financial obligation | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 22, 2021.
The full analysis
What do Journey Medical's filings show?
The filings are where every one of Journey Medical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.